Meeting Overview - The company will hold its second extraordinary general meeting of shareholders on July 18, 2025, at 14:30, combining on-site and online voting methods [1][2] - The online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Procedures - All shareholders registered by July 10, 2025, are entitled to attend the meeting and vote, either in person or by proxy [2][3] - Shareholders can only choose one voting method: on-site or online, with the first valid vote being counted in case of duplicate votes [2][3] Agenda Items - Proposals submitted for voting have been approved by the board and require at least two-thirds of the voting rights held by attending shareholders to pass [3] - The company will separately count and disclose the voting results of minority investors [3] Registration Details - Registration for the meeting can be done on-site, via mail, or email, with specific times and locations provided [4] - Natural persons must present identification and proof of shareholding, while legal entities must provide additional documentation [4] Online Voting Process - The company will provide a platform for online voting, with detailed procedures outlined for shareholders to follow [5][6] - Shareholders must complete identity verification to participate in online voting [5][6] Contact Information - The meeting will take place in Hefei, Anhui Province, with contact details provided for inquiries [5]

Core Viewpoint - The internal audit system of Anhui Huaren Health Pharmaceutical Co., Ltd. aims to ensure compliance, asset security, and the authenticity of financial reporting while enhancing operational efficiency and supporting the company's strategic development [2][4]. Group 1: Internal Control Objectives - Internal control is a process implemented by the board of directors, audit committee, management, and all employees to achieve control objectives [2]. - The goals of internal control include ensuring legal compliance in management, asset security, and the authenticity and completeness of financial reports [2]. Group 2: Internal Audit Structure - The company has established an internal audit department responsible for supervising business activities, risk management, internal controls, and financial information [4][6]. - The internal audit department reports to the board of directors and is supervised by the audit committee [4][6]. Group 3: Responsibilities of Internal Audit - The internal audit department is tasked with evaluating the effectiveness of internal controls, the authenticity of financial information, and the efficiency of business activities [4][5]. - Internal audit personnel must possess professional qualifications and adhere to ethical standards while conducting audits [4][10]. Group 4: Reporting and Evaluation - The internal audit department must report any significant deficiencies or risks in internal controls to the audit committee promptly [5][6]. - The audit committee is responsible for reviewing internal audit reports and providing written assessments of the effectiveness of internal controls to the board of directors [6][8]. Group 5: Compliance and Accountability - The company must disclose any significant deficiencies in internal controls to the Shenzhen Stock Exchange and outline the measures taken to address these issues [6][9]. - Internal audit personnel are protected by laws and regulations, and any obstruction or retaliation against them is prohibited [4][10].

Core Points - The document outlines the management system for the shares held by directors and senior management of Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the need for compliance with relevant laws and regulations [2][3][12] - It specifies the procedures for reporting share transactions by directors and senior management, including timelines for notification and disclosure [4][5][20] - The document establishes restrictions on the transfer of shares by directors and senior management, including limits on the number of shares that can be sold within a year and conditions under which shares cannot be transferred [6][8][19] Group 1 - The management system is established to enhance the oversight of shares held by directors and senior management, in accordance with the Company Law and Securities Law [2][3] - Directors and senior management must notify the board secretary in writing before buying or selling shares, and the board secretary is responsible for managing and verifying the information [4][12] - The document outlines the calculation of transferable shares, stating that newly acquired shares can only be transferred under specific conditions [3][5] Group 2 - Restrictions on share transfers include a maximum of 25% of total shares held per year and a six-month lock-up period after leaving the company [4][6][19] - Certain conditions prohibit directors and senior management from trading shares, such as during the period before financial report announcements and when under investigation for violations [8][18] - The document mandates that any changes in shareholding must be reported to the Shenzhen Stock Exchange within two trading days, including details of the transaction [20][9]

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is revising its Articles of Association to eliminate the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with relevant laws and regulations [1][2][3]. Summary by Sections Reason for Revision - The revision is based on the requirements of the Company Law of the People's Republic of China and related regulations, which state that the supervisory board will no longer be established, and its functions will be assumed by the audit committee of the board of directors [1][2]. Details of the Revision - The specific changes to the Articles of Association include the removal of the supervisory board and the corresponding rules, with updates to terminology such as changing "shareholders' meeting" to "shareholders' assembly" and updating numerical representations [1][2][3]. Other Matters - The board of directors has requested the shareholders' meeting to authorize the management to handle subsequent registration changes and filing of the revised Articles of Association [2][3].

安徽华人健康医药股份有限公司 第一章 总则 第二章 信息披露暂缓与豁免的适用情形 第一条 为规范安徽华人健康医药股份有限公司（以下简称"公司"）信息披 露暂缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资 者的合法权益，根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司信息披露暂缓与豁免管理规定》《深圳证券交 易所创业板股票上市规则》（以下简称"《上市规则》"）等相关法 律法规，并结合《公司章程》及公司《信息披露管理制度》等有关规 定，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露按照中国证券监督管理委员会（以下简称"中国 证监会"）及深圳证券交易所（以下简称"深交所"）规定或者要求披 露的内容，适用本制度。 第三条 公司应当审慎确定信息披露暂缓、豁免事项，并采取有效措施防止暂 缓或者豁免披露的信息泄露。 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者， 不得实施内幕交易、操纵市场等违法行为。 第十四条 公司和其他信息披露义务人应当在年度报告、半 ...

Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Anhui Huaren Health Pharmaceutical Co., Ltd. and protect the interests of minority shareholders [3] - The cumulative voting system allows shareholders to allocate their voting rights across multiple candidates when electing two or more directors, providing flexibility in voting [3][5] - The election process for directors must comply with the company's articles of association and relevant laws, ensuring a structured and transparent nomination and voting process [3][4] Section Summaries General Provisions - The cumulative voting system is established to improve corporate governance and protect minority shareholders' interests, in accordance with relevant laws and regulations [3] - The system allows shareholders to have voting rights equal to the number of shares they hold multiplied by the number of directors to be elected [3] Election and Voting of Directors - The board must inform shareholders about the cumulative voting method before the election, and appropriate ballots must be prepared [2][3] - The election of independent and non-independent directors is conducted separately, with specific voting rights allocated for each category [5] - Shareholders can concentrate or distribute their votes among candidates, but exceeding the allowed number of votes will render the ballot invalid [5] Nomination of Director Candidates - Candidates for the board must be nominated by shareholders holding at least 1% of the company's shares or by the board itself [3] - Nominators must obtain consent from candidates and ensure they meet the qualifications for directorship [3][4] Election Results and Procedures - The number of elected directors must meet the requirements set forth in the company's articles of association, with a majority of votes needed for election [4] - If the number of elected directors is insufficient, additional rounds of voting will be conducted until the required number is met [4]

Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]

安徽华人健康医药股份有限公司 防范控股股东及关联方资金占用管理制度 第一章 总则 第一条 为进一步完善安徽华人健康医药股份有限公司（以下简称"公司"）的法 人治理结构，加强资金管理， 应当严格防止公司 资金被占用。 其他方式向其提供资金； 防止和杜绝控股股东及关联方占用公司资金 行为的发生， 保护公司、股东和其他利益相关方的合法权益。根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司治理准则》、《深 圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》" ）、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》（以下简称"《规范运作指引》"）等法律、法规、规范 性文件和《安徽华人健康医药股份有限公司章程》（以下简称"公司章 程"）等规定，结合公司实际情况，特制定本制度。 经营性资金占用，是指公司控股股东及关联方通过采购、销售等生产经 营环节的关联交易所产生的资金占用；非经营性资金占用，是指公司为 控股股东及关联方垫付工资、福利、保险、广告等费用和其它支出，代 控股股东及关联方偿还债务而支付资金，有偿或无偿、直接 ...

前述担保事项实际发生时，公司应当及时披露，任一时点的担保余额不 得超过股东会审议通过的担保额度。 安徽华人健康医药股份有限公司 对外担保管理制度 第一章 总则 股东会在审议为股东、实际控制人及其关联人提供的担保议案时，该股 东或者受该实际控制人支配的股东，不得参与该项表决，该项表决由出 席股东会的其他股东所持表决权的半数以上通过。 公司为全资子公司提供担保，或者为控股子公司提供担保且控股子公司 其他股东按所享有的权益提供同等比例担保，属于第六条第一款第（一） 项至第（四）项情形的，可豁免提交股东会审议。 第八条 公司为其控股子公司提供担保，如每年发生数量众多、需要经常订立担 保协议而难以就每份协议提交董事会或者股东会审议的，公司可以对资 产负债率为 70%以上以及资产负债率低于 70%的两类子公司分别预计未 来十二个月的新增担保总额度，并提交股东会审议。 第九条 公司为关联人提供担保的，应当在董事会审议通过后及时披露，并提 交股东会审议。 公司对外担保应当要求对方提供反担保。公司为控股股东、实际控制 第一条 为规范安徽华人健康医药股份有限公司（以下简称"公司"）对外担保 行为，确保投资者的合法权益和公司财产安 ...

安徽华人健康医药股份有限公司 第一条 为加强安徽华人健康医药股份有限公司（以下简称"公司"）市值管理 工作，进一步规范公司的市值管理行为，维护公司、投资者及其他利益 相关者的合法权益，依据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司监管指引第 10 号——市值管理》《深圳证券交易所 创业板股票上市规则》等其他有关法律法规，结合公司实际情况，制订 本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公司投 资价值和股东回报能力而实施的战略管理行为。 （一） 合规性原则：公司市值管理行为必须建立在法律法规及监管规则 的基础上实施。 （二） 系统性原则：鉴于公司市值受到多种因素影响，市值管理策略需 遵循系统思考与整体推进的核心理念，全面改善并优化推动市值 增长的关键要素组合。 （三） 科学性原则：市值管理应遵循其固有的客观规律，采取科学严谨 的方法进行市值管理行动，公司须通过科学的市值管理行为，确 保市值管理的科学与高效。 （四） 常态化原则：鉴于公司市值成长是一个长期且动态演变的过程， 市值管理应作为一项持续、常态化的战略任务，不断适应市场变 化，促进市场价值体现。 （五） ...